BMD changes and predictors of increased bone loss in postmenopausal women after a 5‐year course of alendronate

ABSTRACT Management of women discontinuing bisphosphonates after 3 to 5 years of treatment is controversial. Little is known about how much bone mineral density (BMD) is lost after discontinuation or whether there are risk factors for greater rates of bone loss post‐discontinuation. We report patter...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of bone and mineral research 2013-06, Vol.28 (6), p.1319-1327
Hauptverfasser:	McNabb, Brian Louis, Vittinghoff, Eric, Schwartz, Ann V, Eastell, Richard, Bauer, Douglas C, Ensrud, Kristine, Rosenberg, Elizabeth, Santora, Arthur, Barrett‐Connor, Elizabeth, Black, Dennis M
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Factors Aged Aged, 80 and over Alendronate - administration & dosage ALENDRONATE/THERAPEUTIC USE BISPHOSPHONATES BONE DENSITY Bone Density - drug effects Bone Density Conservation Agents - administration & dosage DRUG HOLIDAY DUAL‐ENERGY X‐RAY ABSORPTIOMETRY (DXA) Female Femur Neck - metabolism Femur Neck - pathology Femur Neck - physiopathology Follow-Up Studies Humans Lumbar Vertebrae - metabolism Lumbar Vertebrae - pathology Lumbar Vertebrae - physiopathology Middle Aged Models, Biological Older people OSTEOPOROSIS Osteoporosis, Postmenopausal - drug therapy Osteoporosis, Postmenopausal - metabolism Osteoporosis, Postmenopausal - pathology Osteoporosis, Postmenopausal - physiopathology OSTEOPOROSIS, POSTMENOPAUSE OSTEOPOROSIS/TREATMENT Risk Factors Time Factors Women
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!